DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in NUPLAZID is pimavanserin tartrate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
Generic Entry Opportunity Date for 210793
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 210793
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||CAPSULE;ORAL||Strength||EQ 34MG BASE|
|Approval Date:||Jun 28, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Apr 29, 2021|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||Jan 15, 2024||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS|
|Patent:||Start Trial||Patent Expiration:||Aug 27, 2038||Product Flag?||Y||Substance Flag?||Delist Request?|
Complete Access Available with Subscription